HK1050190A1 - 咪唑衍生物和它們做為raf激酶抑制劑的用途 - Google Patents
咪唑衍生物和它們做為raf激酶抑制劑的用途Info
- Publication number
- HK1050190A1 HK1050190A1 HK03100744.6A HK03100744A HK1050190A1 HK 1050190 A1 HK1050190 A1 HK 1050190A1 HK 03100744 A HK03100744 A HK 03100744A HK 1050190 A1 HK1050190 A1 HK 1050190A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- imidazole derivatives
- raf kinase
- occurred
- excessive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16681499P | 1999-11-22 | 1999-11-22 | |
US16689599P | 1999-11-22 | 1999-11-22 | |
US16688599P | 1999-11-22 | 1999-11-22 | |
US16688699P | 1999-11-22 | 1999-11-22 | |
PCT/GB2000/004413 WO2001038324A2 (en) | 1999-11-22 | 2000-11-20 | Imidazole derivatives and their use as raf kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1050190A1 true HK1050190A1 (zh) | 2003-06-13 |
Family
ID=27496721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03100744.6A HK1050190A1 (zh) | 1999-11-22 | 2003-01-29 | 咪唑衍生物和它們做為raf激酶抑制劑的用途 |
Country Status (21)
Country | Link |
---|---|
US (3) | US7189745B1 (zh) |
EP (2) | EP1233769B1 (zh) |
JP (2) | JP2003514906A (zh) |
KR (1) | KR20020050294A (zh) |
CN (1) | CN1543346A (zh) |
AT (2) | ATE382044T1 (zh) |
AU (2) | AU1623601A (zh) |
BR (1) | BR0015532A (zh) |
CA (1) | CA2395564A1 (zh) |
CZ (1) | CZ20021746A3 (zh) |
DE (2) | DE60015594T2 (zh) |
ES (2) | ES2228629T3 (zh) |
HK (1) | HK1050190A1 (zh) |
HU (1) | HUP0203403A3 (zh) |
IL (2) | IL149150A0 (zh) |
MX (1) | MXPA02005106A (zh) |
NO (1) | NO20022318D0 (zh) |
NZ (1) | NZ518032A (zh) |
PL (1) | PL355912A1 (zh) |
TR (1) | TR200201364T2 (zh) |
WO (2) | WO2001038324A2 (zh) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
CN1543346A (zh) | 1999-11-22 | 2004-11-03 | ʷ��˿�������ȳ�ķ����˾ | 新化合物 |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US20040053943A1 (en) | 2000-11-20 | 2004-03-18 | Adams Jerry L. | Novel compounds |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
WO2003022832A1 (en) * | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Pyridylfurans and pyrroles as raf kinase inhibitors |
GB0121488D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
EP1423383B1 (en) | 2001-09-05 | 2008-08-06 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
WO2003076434A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
CA2494421A1 (en) | 2002-08-06 | 2004-02-12 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
EP1539121A4 (en) | 2002-08-29 | 2008-08-13 | Scios Inc | METHOD OF REQUESTING OSTEOGENESIS |
EP2426122A1 (en) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylene urea derivative as RAF kinasse inhibitors |
RU2005115842A (ru) * | 2002-10-24 | 2006-03-10 | Мерк Патент ГмбХ (DE) | Производные метиленмочевины |
GB0230089D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
EP1581222A2 (en) * | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
WO2005030091A2 (en) | 2003-09-25 | 2005-04-07 | Scios Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
WO2005030151A2 (en) | 2003-10-02 | 2005-04-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US7250434B2 (en) | 2003-12-22 | 2007-07-31 | Janssen Pharmaceutica N.V. | CCK-1 receptor modulators |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
EP1727800A1 (en) * | 2004-02-26 | 2006-12-06 | MERCK PATENT GmbH | Semicarbazide derivatives as kinase inhibitors |
EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
US7807832B2 (en) | 2005-07-28 | 2010-10-05 | Janssen Pharmaceutica Nv | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine |
EP1934213A1 (en) | 2005-09-30 | 2008-06-25 | Astra Zeneca AB | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
UA91129C2 (ru) | 2006-05-09 | 2010-06-25 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит |
CA2689092C (en) | 2007-06-07 | 2013-01-15 | Amgen Inc. | Raf kinase modulators and methods of use |
JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
US8129394B2 (en) * | 2008-03-21 | 2012-03-06 | Novartis Ag | Heteroaryl-substituted imidazole compounds and uses thereof |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
AU2010303363B2 (en) * | 2009-10-08 | 2013-09-05 | Novartis Ag | Combination |
SI2488033T1 (sl) | 2009-10-16 | 2019-10-30 | Novartis Ag | Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF |
US20120270251A1 (en) * | 2009-12-22 | 2012-10-25 | Csir | Inhibition of the activity of kinase and synthetase enzymes |
CN103159735B (zh) * | 2011-12-10 | 2015-12-09 | 通化济达医药有限公司 | 取代的咪唑激酶抑制剂 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
US10605785B2 (en) * | 2017-06-07 | 2020-03-31 | General Electric Company | Sensor system and method |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
US3940486A (en) | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
US4447413A (en) * | 1980-05-08 | 1984-05-08 | Aviation Chemical, Inc. | Drift influencing composition |
US4348404A (en) | 1980-07-21 | 1982-09-07 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines |
DD201677A5 (de) | 1980-07-25 | 1983-08-03 | Ciba Geigy | Verfahren zur herstellung von trisubstituierten imidazolderivaten |
US5166214A (en) | 1988-12-05 | 1992-11-24 | Du Pont Merck Pharmaceutical Company | Use of imidazoles for the treatment of atherosclerosis |
US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
US5179117A (en) | 1991-12-20 | 1993-01-12 | Du Pont Merck Pharmaceutical Company | Antihypercholesterolemic 2-substituted imidazoles |
US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
US5310748A (en) | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
EP0653421B1 (en) | 1993-11-12 | 1997-01-15 | Ishihara Sangyo Kaisha Ltd. | Process for preparing 2-cyanoimidazole compounds |
US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
CA2224563A1 (en) | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
JP2000507545A (ja) | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Cns損傷についての新規な治療 |
CA2250232A1 (en) | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
ATE294174T1 (de) | 1996-06-10 | 2005-05-15 | Merck & Co Inc | Substituierte imidazole mit cytokinin- inhibirender wirkung |
UA67732C2 (uk) | 1996-10-15 | 2004-07-15 | Г.Д. Сьорл & Ко. | Інгібітори циклооксигенази-2 для лікування і попередження неоплазії та спосіб лікування |
DE69835518T2 (de) | 1997-06-12 | 2007-08-09 | Aventis Pharma Ltd., West Malling | Imidazolyl-cyclische acetale |
GB9713726D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
JP2002515915A (ja) | 1997-06-30 | 2002-05-28 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 炎症性疾患の治療で有用な2−置換イミダゾール類 |
US6436966B1 (en) | 1997-10-27 | 2002-08-20 | Takeda Chemical Ind., Ltd. | Adenosine A3 receptor antagonists |
CA2315646C (en) * | 1997-12-22 | 2010-02-09 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
AU765412B2 (en) * | 1997-12-22 | 2003-09-18 | Bayer Healthcare Llc | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
WO1999061437A1 (en) | 1998-05-22 | 1999-12-02 | Smithkline Beecham Corporation | Novel 2-alkyl substituted imidazole compounds |
WO2000001688A1 (fr) | 1998-07-02 | 2000-01-13 | Sankyo Company, Limited | Composes heteroaryle a cinq elements |
US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
AU6476599A (en) * | 1998-11-03 | 2000-05-22 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
WO2000034255A1 (en) | 1998-12-04 | 2000-06-15 | Ontogen Corporation | Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin |
AU4556800A (en) | 1999-04-27 | 2000-11-10 | Smithkline Beecham Plc | Novel treatment |
CN1543346A (zh) | 1999-11-22 | 2004-11-03 | ʷ��˿�������ȳ�ķ����˾ | 新化合物 |
ATE266022T1 (de) | 2000-03-06 | 2004-05-15 | Smithkline Beecham Plc | Imidazol derivate als raf kinase inhibitoren |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
ATE300529T1 (de) | 2000-09-21 | 2005-08-15 | Smithkline Beecham Plc | Imidazolderivate als raf-kinase-inhibitoren |
US20040053943A1 (en) | 2000-11-20 | 2004-03-18 | Adams Jerry L. | Novel compounds |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
WO2003022837A1 (en) | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
WO2003022832A1 (en) | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Pyridylfurans and pyrroles as raf kinase inhibitors |
EP1423383B1 (en) | 2001-09-05 | 2008-08-06 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
-
2000
- 2000-11-20 CN CNA008159491A patent/CN1543346A/zh active Pending
- 2000-11-20 NZ NZ518032A patent/NZ518032A/en unknown
- 2000-11-20 DE DE60015594T patent/DE60015594T2/de not_active Expired - Fee Related
- 2000-11-20 CA CA002395564A patent/CA2395564A1/en not_active Abandoned
- 2000-11-20 IL IL14915000A patent/IL149150A0/xx active IP Right Grant
- 2000-11-20 EP EP00978816A patent/EP1233769B1/en not_active Expired - Lifetime
- 2000-11-20 AT AT00978816T patent/ATE382044T1/de not_active IP Right Cessation
- 2000-11-20 ES ES00977660T patent/ES2228629T3/es not_active Expired - Lifetime
- 2000-11-20 MX MXPA02005106A patent/MXPA02005106A/es unknown
- 2000-11-20 ES ES00978816T patent/ES2298165T3/es not_active Expired - Lifetime
- 2000-11-20 AU AU16236/01A patent/AU1623601A/en not_active Abandoned
- 2000-11-20 KR KR1020027006476A patent/KR20020050294A/ko not_active Application Discontinuation
- 2000-11-20 WO PCT/GB2000/004413 patent/WO2001038324A2/en active IP Right Grant
- 2000-11-20 US US10/130,018 patent/US7189745B1/en not_active Expired - Fee Related
- 2000-11-20 HU HU0203403A patent/HUP0203403A3/hu unknown
- 2000-11-20 WO PCT/US2000/031791 patent/WO2001037835A1/en active Search and Examination
- 2000-11-20 AU AU15299/01A patent/AU1529901A/en not_active Abandoned
- 2000-11-20 CZ CZ20021746A patent/CZ20021746A3/cs unknown
- 2000-11-20 EP EP00977660A patent/EP1232153B1/en not_active Expired - Lifetime
- 2000-11-20 BR BR0015532-2A patent/BR0015532A/pt not_active Application Discontinuation
- 2000-11-20 TR TR2002/01364T patent/TR200201364T2/xx unknown
- 2000-11-20 PL PL00355912A patent/PL355912A1/xx not_active Application Discontinuation
- 2000-11-20 JP JP2001540087A patent/JP2003514906A/ja not_active Withdrawn
- 2000-11-20 AT AT00977660T patent/ATE281451T1/de not_active IP Right Cessation
- 2000-11-20 US US10/130,019 patent/US7026336B1/en not_active Expired - Fee Related
- 2000-11-20 JP JP2001539450A patent/JP2003514860A/ja active Pending
- 2000-11-20 DE DE60037597T patent/DE60037597T2/de not_active Expired - Fee Related
-
2002
- 2002-04-15 IL IL149150A patent/IL149150A/en not_active IP Right Cessation
- 2002-05-15 NO NO20022318A patent/NO20022318D0/no not_active Application Discontinuation
-
2003
- 2003-01-29 HK HK03100744.6A patent/HK1050190A1/zh unknown
-
2006
- 2006-09-19 US US11/533,034 patent/US20070010534A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1050190A1 (zh) | 咪唑衍生物和它們做為raf激酶抑制劑的用途 | |
YU65502A (sh) | Supstituisani beta-karbolini sa ikb-kinaza inhibirajućim dejstvom | |
EP1343779A4 (en) | NEW COMPOUNDS | |
PL361397A1 (en) | Imidazole derivatives as raf kinase inhibitors | |
BG105625A (en) | Quinoline and quinoxaline compounds as pfgf-receptor and/or lck tyrosine kinase inhibitors | |
BG106585A (en) | Kinase inhibitors as therapeutic agents | |
MY128370A (en) | Pyrrolotriazane inhibitors of kinases | |
TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
RS20050042A (en) | Novel inhibitors of kinases | |
JO2503B1 (en) | Benzathiazole derivatives | |
NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
IL148903A0 (en) | Certain alkylene diamine-substituted heterocycles | |
MXPA04005886A (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6. | |
MXPA04003087A (es) | Derivados de cromano como ligados de 5-hidroxitriptamina-6. | |
NZ513096A (en) | Compositions for treating inflammatory response | |
WO2002051832A3 (en) | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | |
ES2249309T3 (es) | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. | |
ES2184097T3 (es) | Nuevos compuestos. | |
EP1372648A4 (en) | KIEASE TIE2 RECEPTOR INHIBITORS FOR THE TREATMENT OF ANGIOGENIC DISEASES | |
NZ504124A (en) | Phenyl-alkyl-imidazoles and use in treating inflammatory disease | |
MXPA04001977A (es) | Antagonistas v de receptor ccr-3. | |
MXPA02002007A (es) | Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos. | |
WO2000046193A3 (en) | Ether derivatives having neuronal activity |